目的 探討金酸萍顆粒聯(lián)合替諾福韋治療慢性乙型肝炎的臨床療效。方法 選取2021年11月-2023年2月海南醫(yī)學(xué)院第一附屬醫(yī)院收治的慢性乙型肝炎患者120例,隨機(jī)法分為對(duì)照組(60例)和治療組(60例)。對(duì)照組患者口服富馬酸替諾福韋二吡呋酯片,1片/次,1次/d。在對(duì)照組的基礎(chǔ)上,治療組口服金酸萍顆粒,15 g/次,1次/d。兩組連續(xù)服用藥12周。觀察兩組患者臨床療效,比較治療前后兩組患者癥狀改善時(shí)間,生活質(zhì)量評(píng)分,肝功能丙氨酸氨基轉(zhuǎn)移酶(ALT)、天門冬氨酸氨基轉(zhuǎn)移酶(AST)、總膽紅素(TBIL)和谷氨酰轉(zhuǎn)肽酶(GGT)指標(biāo),及血清炎性因子白細(xì)胞介素-17(IL-17)、轉(zhuǎn)化生長(zhǎng)因子-β1(TGF-β1)、腫瘤壞死因子-α(TNF-α)和白細(xì)胞介素-6(IL-6)水平。結(jié)果 治療后,治療組患者臨床總有效率為98.33%,明顯高于對(duì)照組(85.00%,P<0.05)。治療后,治療組癥狀改善時(shí)間均早于對(duì)照組(P<0.05)。治療后,兩組患者的生活質(zhì)量改善QOL-C30評(píng)分明顯升高(P<0.05),且治療組QOL-C30評(píng)分明顯高于對(duì)照組(P<0.05)。治療后,兩組患者ALT、AST、TBIL、GGT、TGF-β1、IL-17、TNF-α、IL-6水平指標(biāo)均明顯下降(P<0.05),且治療組患者指標(biāo)水平均明顯低于對(duì)照組(P<0.05)。結(jié)論 金酸萍顆粒聯(lián)合替諾福韋治療慢性乙型肝炎效果確切,可明顯改善臨床癥狀,有效調(diào)節(jié)肝功能狀態(tài),并減弱機(jī)體炎性反應(yīng),患者生活質(zhì)量提高。

Objective To explore the clinical study of Jinsuanping Granules combined with tenofovir in the treatment of chronic hepatitis. Methods Patients (120 cases) with chronic hepatitis in the First Affiliated Hospital of Hainan Medical university from November 2021 to February 2023 were randomly divided into control (60 cases) and treatment (60 cases) group. Patients in the control group were po administered with Tenofovir Disoproxil Fumarate Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Jinsuanping Granules on the basis of the control group, 15 g/time, once daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical evaluation was evaluated, and the improvement time of symptom, quality of life score, the liver function indicators ALT, AST, TBIL and GGT, the serological levels of TGF-β1, IL-17, TNF-α and IL-6 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 98.33%, which was significantly higher than that of the control group (85.00%, P < 0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the QOL-C30 score of quality of life improved significantly in two groups (P < 0.05), and the QOL-C30 score in the treatment group was significantly higher than that in the control group (P < 0.05). After treatment, the levels of ALT, AST, TBIL GGT, TGF-β1, IL-17, TNF-α and IL-6 in two groups were significantly lower than those before treatment (P < 0.05), and the levels of these indexes in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Jinsuanping Granules combined with tenofovir in treatment of chronic hepatitis is effective, which can obviously improve the clinical symptoms, effectively regulate the liver function, weaken the inflammatory reaction, and improve the quality of life of the patients.

R978.7

海南省自然科學(xué)基金面上項(xiàng)目(819MS122)